Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients

Experimental and Clinical Transplantation

Volumn 8, Issue 1, 2010, Pages 66-73

  Iravani, Masoud ^a   Tavakoli, Emytis ^a   Babaie, Molouk Hadji ^a   Ashouri, Asiyeh ^a   Khatami, Farnaz ^b   Ghavamzadeh, Ardeshir ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

thalassemia class 3; Graft versus host disease; Transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEUKOCYTE ANTIGEN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; RECURRENT DISEASE; SCHOOL CHILD; SIBLING; SURVIVAL RATE; THALASSEMIA; THROMBOCYTE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; THALASSEMIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77749321092     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rund D, Rachmilewitz E. New trends in the treatment of betathalassemia. Crit Rev Oncol Hematol. 2000;33(2):105-118.
2. Thomas ED, Buckner CD, Sanders JE, et al. Marrow transplantation for thalassemia. Lancet. 1982;2(8292):227-229.
3. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104(4):1201-1203.
4. Lucarelli G, Polchi P, Galimberti M, et al. Marrow transplantation for thalassemia following busulphan and cyclophosphamide. Lancet. 1985;1(8442):1355-1357.
5. Lucarelli G, Giardini C, Baronciani D. Bone marrow transplantation in thalassemia. Semin Hematol. 1995;32(4):297-303.
6. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood. 1996;87(5):2082-2088.
7. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421.
8. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000;95(12):3702-3709.
9. Levine JE, Wiley J, Kletzel M, et al. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD. Bone Marrow Transplant. 2000;25(1):13-18.
10. Li CK, Yuen PM, Chik KW, et al. Allogeneic peripheral blood stem cell transplant in children. Med Pediatr Oncol. 1998;30(3):147-151.
11. Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98(6):1695-1700.
12. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415-419.
13. Ghavamzadeh A, Iravani M, Ashouri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant. 2008;14(3):301-308.
14. Yesilipek MA, Hazar V, Kupesiz A, Kizilors A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with betathalassemia. Bone Marrow Transplant. 2001;28(11):1037-1040.
15. Pakakasama S, Hongeng S, Chaisiripoomkere W, Chuansumrit A, Sirachainun N, Jootar S. Allogeneic peripheral blood stem cell transplantation in children with homozygous beta-thalassemia and severe beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2004;26(4):248-252.
16. Irfan M, Hashmi K, Adil S, et al. Beta-thalassemia major: bone marrow versus peripheral blood stem cell transplantation. J Pak Med Assoc. 2008;58(3):107-110.
17. Diaz MA, Kanold J, Vicent MG, Halle P, Madero L, Demeocq F. Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. Bone Marrow Transplant. 2000;26(12):1291-1298.
18. Iravani M, Mousavi A, Gholibeikian S, et al. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2005;35(11):1095-1099.
19. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42(6):397-404.
20. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after human leukocyte antigen-identical sibling bone marrow transplantation. Blood. 2002;99(8):2726-2733.